scholarly journals Decreased Platelet Thrombus Size, Due to a Heightened Proteolysis of VWF By ADAMTS13, Is Quickly Restored after Valve Replacement in Aortic Stenosis Patients

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 2857-2857
Author(s):  
Hideo Yagi ◽  
Masaki Hayakawa ◽  
Naoko Yamaguchi ◽  
Keigo Yamashita ◽  
Shigeki Taniguchi ◽  
...  

Abstract Background: The patients with severe aortic-valve stenosis (AS) are often complicated with bleeding episodes. The association between AS and gastrointestinal bleeding due to angiodysplasia is reported as Heyde's syndrome, which is categorized as one of the acquired von Willebrand disease (AVWD) in cardiovascular disorders. An international survey has shown that Type 2A is the common subtype of AVWD in the patients with AS. AVWD Type 2A is characterized by impaired platelet-dependent VWF function caused by marked decrease or absence of the most hemostatically active HMW-VWFM. In the patients with AS, a significant correlation between the increased high shear stress and loss of HMW-VWFM in vivo. Further, the absence of HMW-VWFM and bleeding tendency are normalized after valve replacement. These results suggest that enhanced proteolysis of von Willebrand factor (VWF) as it passes through the stenotic valve may induce the loss of HMW-VWFM because high shear stress can induce structure changes in VWF, which is sensitive form to the VWF cleaving protease, termed ADAMTS13. Here, we performed investigation of plasma levels of VWF antigen (VWF:Ag), ADAMTS13 activity (ADAMTS13:AC), and platelet thrombus formation in the patients with AS by valve replacement to confirm the pathophysiological mechanism of this rare disease. Patients and Methods: Ten consecutive patients who underwent aortic valve replacement for AS in Nara Medical University Hospital were enrolled in this study. The severity of AS was judged by the American Heart Association guideline. All patients had no bleeding history and received bovine tissue valves replacement followed by administration of warfarin and/or anti-platelet agents for prevention of thrombosis a week after surgery. We collected a series of blood samples from these patients before and day1, 8, 15, 22 after valve replacement. Excluding one patient who developed critical cardiac failure just after valve replacement, 9 patients were eventually evaluated by analyses of VWF:Ag, VWF multimers, ADAMTS13:AC, and mural thrombus formation using flow chamber system. VWF:Ag was measured by sandwich ELISA using a rabbit anti-human VWF polyclonal antiserum. Analysis of VWF multimers was performed according to the method of Ruggeri and Zimmerman. ADAMTS13:AC was measured by a chromogenic ADAMTS13-act-ELISA. Platelet thrombus formation was evaluated by thrombus generation under a high shear stress in a parallel plate flow chamber system. Briefly, whole blood anti-coagulated with argatroban was incubated with the fluorescent dye DiOC6 (1uM), and these samples containing DiOC6 -labeled platelets were perfused for 7 min over a type I collagen-coated glass surface under a high shear rate (1500 s-1). The DiOC6 fluorescence corresponding to the platelets was examined at an excitation wavelength of 488 nm with a barrier filter at 500 nm. The percentage of the area covered by adhering platelets (surface coverage) and each thrombus volume were evaluated. Results: Plasma levels of VWF:Ag before surgery were 78.1 % (median) and those on day 1, 8, 15, 22 after surgery were 130, 224, 155, and 134 %, respectively (Fig 1). Conversely, these levels of ADAMTS13:AC were 50.5, 35.5, 25.5, 25.1, and 30.3 %, respectively (Fig 2). The ratio of VWF:Ag/ADAMTS13:AC at before and day 1, 8, 15, 22 after surgery were 1.6, 4.5, 8.1, 6.1, and 4.1, respectively. In VWF multimer analysis, we found the obvious defect of HMW-VWFM in 7 of 9 patients before surgery, who were diagnosed with severe AS. The remaining two patients had moderate AS with the slight defect of HMW-VWFM. These defects were improved within 14 days after surgery. In platelet thrombus formation, the amount of thrombus volumes significantly increased at day 8, 15, and 22 after compared with before surgery (Fig 3). Conclusion: The dramatic recovery of platelet thrombus formation was observed in the patients with AS by valve replacement. The rapid increment of VWF and normalization of VWFM pattern, together with reduction of ADAMTS13 after valve replacement suggested heightened proteolysis of VWF by ADAMTS13 under high shear stress would be a major cause of this unique bleeding complication. The highest ratio of VWF:Ag/ADAMTS13:AC at day 8 after surgery might imply the necessity of blockade of heightened VWF function with anti-platelet agents. Figure 1 Figure 1. Disclosures Matsumoto: Alfresa Pharma Corporation: Patents & Royalties. Fujimura:Alfresa Pharma Corporation: Patents & Royalties.

Blood ◽  
1995 ◽  
Vol 85 (3) ◽  
pp. 705-711 ◽  
Author(s):  
J Harsfalvi ◽  
JM Stassen ◽  
MF Hoylaerts ◽  
E Van Houtte ◽  
RT Sawyer ◽  
...  

Calin from the saliva of the medicinal leech, Hirudo medicinalis, is a potent inhibitor of collagen mediated platelet adhesion and activation. In addition to inhibition of the direct platelet-collagen interaction, we presently demonstrate that binding of von Willebrand to coated collagen can be prevented by Calin, both under static and flow conditions in agreement with the occurrence of binding of Calin to collagen, confirmed by Biospecific Interaction Analysis. To define whether Calin acted by inhibiting the platelet-collagen or the platelet- von Willebrand factor (vWF)-collagen-mediated thrombus formation, platelet adhesion to different types of collagens was studied in a parallel-plate flow chamber perfused with whole blood at different shear rates. Calin dose-dependently prevented platelet adhesion to the different collagens tested both at high- and low-shear stress. The concentration of Calin needed to cause 50% inhibition of platelet adhesion at high-shear stress was some fivefold lower than that needed for inhibition of vWF-binding under similar conditions, implying that at high-shear stress, the effect of Calin on the direct platelet- collagen interactions, suffices to prevent thrombus formation. Platelet adhesion to extracellular matrix (ECM) of cultured human umbilical vein endothelial cells was only partially prevented by Calin, and even less so at a high-shear rather than a low-shear rate, whereas the platelet binding to coated vWF and fibrinogen were minimally affected at both shear rates. Thus, Calin interferes with both the direct platelet- collagen interaction and the vWF-collagen binding. Both effects may contribute to the inhibition of platelet adhesion in flowing conditions, although the former seems to predominate.


Blood ◽  
2001 ◽  
Vol 98 (6) ◽  
pp. 1828-1835 ◽  
Author(s):  
Marina Morigi ◽  
Miriam Galbusera ◽  
Elena Binda ◽  
Barbara Imberti ◽  
Sara Gastoldi ◽  
...  

Abstract Verotoxin-1 (VT-1)–producing Escherichia coli is the causative agent of postdiarrheal hemolytic uremic syndrome (D+HUS) of children, which leads to renal and other organ microvascular thrombosis. Why thrombi form only on arterioles and capillaries is not known. This study investigated whether VT-1 directly affected endothelial antithrombogenic properties promoting platelet deposition and thrombus formation on human microvascular endothelial cell line (HMEC-1) under high shear stress. Human umbilical vein endothelial cells (HUVECs) were used for comparison as a large-vessel endothelium. HMEC-1 and HUVECs were pre-exposed for 24 hours to increasing concentrations of VT-1 (2-50 pM) and then perfused at 60 dynes/cm2 with heparinized human blood prelabeled with mepacrine. Results showed that VT-1 significantly increased platelet adhesion and thrombus formation on HMEC-1 in comparison with unstimulated control cells. An increase in thrombus formation was also observed on HUVECs exposed to VT-1, but to a remarkably lower extent. The greater sensitivity of HMEC-1 to the toxin in comparison with HUVECs was at least in part due to a higher expression of VT-1 receptor (20-fold more) as documented by FACS analysis. The HMEC-1 line had a comparable susceptibility to the thrombogenic effect of VT-1 as primary human microvascular cells of the same dermal origin (HDMECs). The adhesive molecules involved in VT-induced thrombus formation were also studied. Blocking the binding of von Willebrand factor to platelet glycoprotein Ib by aurintricarboxylic acid (ATA) or inhibition of platelet αIIbβ3-integrin by chimeric 7E3 Fab resulted in a significant reduction of VT-1–induced thrombus formation, suggesting the involvement of von Willebrand factor–platelet interaction at high shear stress in this phenomenon. Functional blockade of endothelial β3-integrin subunit, vitronectin receptor, P-selectin, and PECAM-1 with specific antibodies was associated with a significant decrease of the endothelial area covered by thrombi. Confocal microscopy studies revealed that VT-1 increased the expression of vitronectin receptor and P-selectin and redistributed PECAM-1 away from the cell-cell border of HMEC-1, as well as of HDMECs, thus indicating that the above endothelial adhesion molecules are directly involved and possibly determine the effect of VT-1 on enhancing platelet adhesion and thrombus formation in microvascular endothelium. These results might help to explain why thrombi in HUS localize in microvessels rather than in larger ones and provide insights on the molecular events involved in the process of microvascular thrombosis associated with D+HUS.


2006 ◽  
Vol 81 (2) ◽  
pp. 490-494 ◽  
Author(s):  
Kazunori Yoshida ◽  
Satoshi Tobe ◽  
Masahito Kawata ◽  
Masahiro Yamaguchi

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 849-849
Author(s):  
David Varon ◽  
Boris Shenkman ◽  
Ulrich Budde ◽  
Dorothea Angerhaus ◽  
Reinhard Schneppenheim ◽  
...  

Abstract The metalloprotease ADAMTS-13 cleaves von Willebrand factor (VWF) that is released from endothelial cells as a large multimeric protein. However, the specific physiological conditions required for the function of this von Willebrand factor-cleaving protease (VWF-CP) are not yet established. In this study we determined the optimal conditions for the VWF-CP activity using the Cone and Plate(let) Analyzer (CPA). Proteolysis of a soluble recombinant VWF by a recombinant VWF-CP in the absence or the presence of BaCl2 (for induction of VWF-CP) was performed under static and flow (2050 s−1) conditions. The resulted fragments of the soluble VWF were immobilized on a polystyrene surface and non-adhering sites were blocked with 1% BSA. In parallel, polystyrene surface immobilized VWF was similarly treated by VWF-CP. The immobilized cleaved VWF fragments by the above protocols served as a substrate for citrated whole blood platelet adhesion under flow (2050 s−1). Reduction of platelet adhesion (surface coverage, SC) in BaCl2 treated compared to untrerated sample reflects the degree of VWF-CP activity. Platelet adhesion (SC, %) to VWF proteolytic products generated under the indicated conditions: Static w/o BaCl2 Static + BaCl2 Flow w/o BaCl2 Flow + BaCl2 Soluble VWF 15.0 ± 3.4 11.1 ± 2.7 13.6 ± 2.2 8.0 ± 2.1 Immobil. VWF 19.1 ± 3.0 12.0 ± 4.1 6.5 ± 1.1 1.0 ± 0.6 Maximal VWF-CP activity as reflected by maximal reduction (85%) of platelet adhesion was observed when immobilized VWF was treated by VWF-CP under flow. Minimal effect of VWF-CP activity was observed when soluble VWF was treated under static condition (26% reduction). Intermediate effect was observed with soluble VWF under flow (41%) and with immobilized VWF under static condition (37%). It should be noted that in the case of immobilized VWF application of flow alone (without BaCl2) was sufficient to induce a remarkable decrease of platelet adhesion (66%). In conclusion, both immobilization of VWF and high shear stress are important conditions for VWF-CP function, suggesting that stretching of immobilized VWF under flow exposes the VWF-cleavage site and thereby may serve as a control mechanism of platelet adhesion at the site of thrombus formation.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 1556-1556
Author(s):  
Junmei Chen ◽  
Jody L. Whitelock ◽  
Lisa D. Morales ◽  
Jose A. Lopez ◽  
Miguel A. Cruz

Abstract Integrin α2β1 (GP Ia/IIa) is a major platelet receptor for collagen, containing its collagen binding site within the α2 I domain. α2β1 changes conformation upon platelet activation, increasing its affinity for collagen. The conformational changes are reflected in the markedly different crystal structures obtained for the α2 I domain depending on whether it is free or bound to a collagen peptide. However, it is not known whether in flowing blood α2β1 on platelets is activated before binding to collagen. To address this issue, we identified an antibody that has higher affinity for the activated α2β1. We found that two antibodies that bind within the α2 I domain, 12F1 and 6F1, bound preferentially to ADP-activated platelets, with 12F1 displaying the most marked increase in binding with activation. We corroborated this result for 12F1 by showing that it binds with higher affinity to a gain-of-function I domain mutant than to either the wild-type I domain or to a loss-of-function mutant. In addition, when whole blood was perfused over a surface coated with 12F1, the antibody did not support the adhesion of unstimulated platelets. Because thrombus formation on collagen at a high shear stress is initiated by the binding of the platelet glycoprotein Ib-IX-V complex (GP Ib) to von Willebrand factor (VWF), we tested whether this interaction can activate α2β1, using 12F1 as a probe for integrin activation. We perfused blood over a surface coated with a mixture of VWF A1 domain (a GP Ib ligand) and 12F1, or VWF A1 and mouse IgG. Platelets rolled and did not attach stably on the A1/IgG surface, but they firmly bound and covered the A1/12F1 surface. The fact that 12F1 alone failed to capture resting platelets under flow but supported firm platelet adhesion if GP Ib interacted with VWF A1 strongly suggests that GP Ib ligation by VWF induces signals that activate α2β1 and increase its affinity for collagen. The two receptors (GP Ib and α2β1) then cooperate in platelet adhesion to collagen, which was demonstrated by perfusing, at a high shear stress, reconstituted blood lacking VWF and fibrinogen over surfaces coated with collagen or A1/collagen. The A1/collagen surface contained more firmly adherent platelets than the collagen surface; firm adhesion was blocked by 6F1. We then tested whether the signals from GP Ib and α2β1 cooperate to fully activate platelets and allow thrombus growth. For this, we perfused whole blood over a mixed matrix of A1 and the α2β1-specific type I collagen-derived triple-helical peptide, CP10. We observed that platelets not only firmly adhered to this surface, they also formed thrombi, similar to those seen on collagen surfaces. Thrombus formation was inhibited by either the αIIbβ3 antibodies or blocking the A1/CP10 surface with the recombinant α2 I domain. Together, our data indicate that platelets adhere to collagen in a stepwise fashion, beginning with the interaction of GP Ib with VWF, which rapidly activates α2β1 to engage collagen. The combination of adhesive ligand-receptor interactions induces the activation of integrin αIIbβ3, which enables thrombus formation.


2000 ◽  
Vol 84 (10) ◽  
pp. 727-728 ◽  
Author(s):  
Agnès Veyradier ◽  
Edith Fressinaud ◽  
Catherine Boyer-Neumann ◽  
Marc Trossaert ◽  
Dominique Meyer

Blood ◽  
1998 ◽  
Vol 91 (4) ◽  
pp. 1325-1331 ◽  
Author(s):  
Edith Fressinaud ◽  
Agnès Veyradier ◽  
Florence Truchaud ◽  
Isabelle Martin ◽  
Catherine Boyer-Neumann ◽  
...  

AbstractWe have evaluated the performance of a new analyzer using high shear stress, the PFA-100 (Platelet Function Analyzer, Dade International, Massy, France), for screening of patients with von Willebrand disease (vWD). Whole citrated blood is aspirated through a capillary to the central aperture of a membrane coated with collagen and with a platelet agonist (either epinephrine or adenosine diphosphate [ADP]). The time required to obtain occlusion of the aperture by a platelet plug is defined as the closure time (CT). We studied 60 patients with different types of vWD and 96 normal subjects. Fourteen subjects with hemophilia and 15 patients with a platelet disorder were also analyzed. When omitting results from two patients with type 2N, the 58 other patients with type 1, type 2A, type 2B, type 3, or acquired vWD all exhibited an abnormal occlusion with collagen-ADP (sensitivity, 100%) and 56 of 58 had an abnormal CT with collagen-epinephrine (sensitivity, 96.5%). Only two patients with mild type 1 were not detected with collagen-epinephrine. In comparison, the bleeding time (BT) was normal in 20 patients: 17 with type 1, two with type 2A, and one with acquired vWD (sensitivity, 65.5%). The specificity of the PFA-100 was over 95% with both types of cartridges. Thus, the analyzer is well adapted to routine testing, as it has the advantages of simplicity and ease of execution, and demonstrates a high sensitivity, clearly superior to that of BT, for the screening of patients with vWD.


ASAIO Journal ◽  
2001 ◽  
Vol 47 (2) ◽  
pp. 171
Author(s):  
M. Kawamura ◽  
J. Linneweber ◽  
H. Ishitoya ◽  
T. Motomura ◽  
M. Mikami ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document